Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma

• Autores: Iglesias, Rebeca, Díaz, Eva, Fernández, Sara, Miguélez, Marta, Torres, María De Rosa, Domínguez, Mirna L., Solórzano, José L., Estévez, Mónica, Oña, Raquel, M. Bobes, Alejandro, Montalbán, Carlos, de la Fuente, Adolfo, García, Juan F.
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/473
• Enlace del recurso: https://doi.org/10.3324/haematol.2024.286579; https://hdl.handle.net/20.500.14703/473
• Nivel de acceso: acceso abierto
• Materia: Clonal hematopoiesis; Hodgkin lymphoma; https://purl.org/pe-repo/ocde/ford#3.02.21

The term ‘clonal hematopoiesis of indeterminate potential’ (CHIP) was first introduced by Steensma et al. for individuals carrying somatic leukemia-associated mutations with a variant allele frequency (VAF) ≥2%.1 Aging is strongly associated with the prevalence of CHIP. In the young age group (<45 years), mutations have been found in <1% of cases.2,3 In elderly people (>60 years), the phenomenon of clonal hematopoiesis is present in 10-15% of people.4 The clonal expansions most frequently involve somatic mutations in genes that have previously been implicated in hematologic cancers (DNMT3A, ASXL1, TET2, etc.),5 especially myelodysplastic syndromes and myeloid leukemias. It is now widely accepted that mutations can also be detected in genes that are recurrently mutated in lymphoid malignancies, thus CHIP should be distinguished into myeloid CHIP (M-CHIP) and lymphoid CHIP (L-CHIP).